Key clinical point: An oral selective Janus kinsase 1 and 2 inhibitor shows promise for the treatment of alopecia areata.

Major finding: Of alopecia areata patients on the top dose of an investigational oral JAK1/2 inhibitor for 24 weeks, 58% experienced at least a 50% reduction in baldness, versus 9% of those on placebo.

Study details: This was a phase 2, double-blind, placebo-controlled, 24-week, randomized trial including 149 adults with moderate or severe alopecia areata.

Disclosures: The study was sponsored by Concert Pharmaceuticals and presented by a company officer.